Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood

• Publication date

  2017-11-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2017-06-792150PMID 28972015PMCID PMC5680613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

  2017cited by this paper
• FISH Panel for Leukemic CTCL.

  2017cited by this paper
• Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma

  2017cited by this paper
• Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

  2017cited by this paper
• Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.

  2016cited by this paper
• STAT5 induces miR-21 expression in cutaneous T cell lymphoma

  2016cited by this paper
• A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia

  2016cited by this paper
• Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

  2016cited by this paper
• TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL

  2015cited by this paper
• Genomic landscape of cutaneous T cell lymphoma

  2015cited by this paper
• Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

  2015cited by this paper
• Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

  2015cited by this paper
• Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

  2015cited by this paper
• The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)

  2015cited by this paper
• Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.

  2015cited by this paper
• Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

  2015cited by this paper
• MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

  2015cited by this paper
• Romidepsin targets multiple survival signaling pathways in malignant T cells

  2015cited by this paper
• ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

  2015cited by this paper
• Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

  2015cited by this paper
• Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL

  2015cited by this paper
• The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome

  2015cited by this paper
• Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199

  2014cited by this paper
• ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

  2014cited by this paper
• BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

  2014cited by this paper
• The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells

  2014cited by this paper
• Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.

  2014cited by this paper
• Activity of ABT-199 and Acquired Resistance in Follicular Lymphoma Cells

  2014cited by this paper
• Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion

  2014cited by this paper
• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME

  2014cited by this paper
• Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

  2013cited by this paper
• Small-molecular modulators of cancer-associated epigenetic mechanisms.

  2013cited by this paper
• MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

  2013cited by this paper
• BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

  2012cited by this paper
• Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Romidepsin for cutaneous T-cell lymphoma.

  2012cited by this paper
• Romidepsin for Cutaneous T-cell Lymphoma

  2012cited by this paper
• Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells

  2011cited by this paper
• Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.

  2011cited by this paper
• Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters

  2011cited by this paper
• Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

  2010cited by this paper
• Novel approach to gene expression profiling in Sézary syndrome

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

  2009cited by this paper
• Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.

  2009cited by this paper
• Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

  2009cited by this paper
• Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation.

  2008cited by this paper
• Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

  2008cited by this paper
• Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

  2008cited by this paper
• Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

  2007cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas

  2006cited by this paper
• STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells.

  2005cited by this paper
• Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.

  2005cited by this paper
• Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis

  2004cited by this paper
• The pathogenesis of mycosis fungoides.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

  2004cited by this paper
• Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma

  2003cited by this paper
• Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.

  2001cited by this paper
• Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells

  1999cited by this paper
• Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides

  1992cited by this paper
• A clonal CD4-positive T-cell line established from the blood of a patient with Sézary syndrome.

  1991cited by this paper
• Establishment of an IL‐2 independent, human T‐cell line possessing only the p70 IL‐2 receptor

  1991cited by this paper
• Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas.

  1980cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• Hierarchical Grouping to Optimize an Objective Function

  1963cited by this paper

• The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir

  2026cites this paper
• HDAC10 and its implications in Sézary syndrome pathogenesis

  2025cites this paper
• Synergistic anticancer effects of ABT-199 and Vorinostat encapsulated in PLGA nanoparticles: Formulation, characterization, and antiproliferative effects against colorectal cancer cells

  2025cites this paper
• Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma

  2025cites this paper
• Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K/AKT/mTOR Dephosphorylation

  2025cites this paper
• Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors

  2025cites this paper
• Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening

  2024cites this paper
• A Yale Dermatology Perspective on Cutaneous T-Cell Lymphoma: Historical Reflection to Emerging Therapies.

  2024cites this paper
• Genomic analysis reveals molecular characterization of CD30+ and CD30- extranodal natural killer/T-cell lymphomas (ENKTLs).

  2024cites this paper
• H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma

  2024cites this paper
• Obstructive sleep apnea hypopnea syndrome and vascular lesions: An update on what we currently know.

  2024cites this paper
• Proteasome Inhibitors Interact Synergistically with BCL2, HDAC, BET, and JAK Inhibitors Against CTCL Cells.

  2023cites this paper
• The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis

  2023cites this paper
• Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers

  2023cites this paper
• Violaceous Lesions on the Leg: What Else Apart from Kaposi Sarcoma? Differential Diagnosis with a Narrative Review of the Literature

  2023cites this paper
• Harnessing the immune system in the treatment of cutaneous T cell lymphomas

  2023cites this paper
• Prime, shock and kill: BCL-2 inhibition for HIV cure

  2022cites this paper
• Sensitivity of canine hematological cancers to BH3 mimetics

  2022cites this paper
• Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma

  2022cites this paper
• Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma

  2021cites this paper
• PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer

  2021cites this paper
• Novel therapies targeting cutaneous T cell lymphomas and their microenvironment.

  2021cites this paper
• Targeting epigenetic mechanisms to overcome venetoclax resistance.

  2021cites this paper
• 83JAK-STAT inhibition mediates romidepsin and mechlorethamine synergism in Cutaneous T-cell Lymphoma.

  2021cites this paper
• Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma

  2021cites this paper
• Uncovering the potential of PI3K inhibitors in cutaneous T cell lymphoma: insights from high throughput in vitro screenings.

  2021cites this paper
• Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia

  2021cites this paper
• Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs

  2021cites this paper
• The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides

  2021cites this paper
• Epigenetic polypharmacology: A new frontier for epi‐drug discovery

  2020cites this paper
• Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development.

  2020cites this paper
• JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

  2020influential citation
• Can we use epigenetics to prime chemoresistant lymphomas?

  2020cites this paper
• Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma

  2020cites this paper
• Integrative data modeling from lung and lymphatic cancer predicts functional roles for miR-34a and miR-16 in cell fate regulation

  2020cites this paper
• B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma

  2020cites this paper
• Novel targeted therapies of T cell lymphomas

  2020cites this paper
• AGGRESSIVE LYMPHOMAS: WHAT NOVEL APPROACHES ARE READY FOR PRIME TIME? Can we use epigenetics to prime chemoresistant lymphomas?

  2020cites this paper
• Prognostic significance of Bcl-2 expression in primary cutaneous B-cell lymphoma: a reappraisal.

  2020cites this paper
• Enhancing venetoclax activity in hematological malignancies

  2020cites this paper
• Unique Therapeutic Approaches for Targeting Epigenetic Machinery in T-cell Lymphoma

  2019cites this paper
• Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma

  2019cites this paper
• Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.

  2019cites this paper
• Combined inhibition of Bcl-2 and NFκB synergistically induces cell death and limits xenograft mouse tumor growth in CTCL.

  2019cites this paper
• Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma

  2019cites this paper
• Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.

  2019cites this paper
• Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients

  2019influential citation
• Small molecule inhibitors for cutaneous T-cell lymphomas

  2018cites this paper
• BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition

  2018cites this paper
• The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

  2018cites this paper
• The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease

  2018cites this paper